BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-14 17:02 |
CHMP ger positiv rekommendation för godkännande av lecanemab i EU
|
Swedish | 218.5 KB | ||
| 2024-11-14 08:00 | English | 1.2 MB | |||
| 2024-11-08 05:00 |
Eisai uppdaterar försäljningsprognosen för Leqembi® till 42,5 miljarder JPY för…
|
Swedish | 196.9 KB | ||
| 2024-11-08 05:00 |
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). …
|
English | 172.1 KB | ||
| 2024-11-01 00:30 |
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of L…
|
English | 198.0 KB | ||
| 2024-11-01 00:30 |
Eisai slutför stegvis ansökan för subkutan underhållsbehandling med Leqembi® (l…
|
Swedish | 184.3 KB | ||
| 2024-10-30 11:45 |
Försäljningen av Leqembi® uppgick till 10 miljarder yen under det tredje kvarta…
|
Swedish | 174.4 KB | ||
| 2024-10-11 08:30 |
BioArctic presents Nomination Committee
|
English | 185.1 KB | ||
| 2024-09-30 18:30 |
Number of shares and votes in BioArctic AB (publ) as of September 30, 2024
|
English | 139.1 KB | ||
| 2024-08-29 08:00 | Swedish | 9.4 MB | |||
| 2024-08-29 08:00 | English | 8.7 MB | |||
| 2024-08-22 11:06 |
Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
|
English | 236.2 KB | ||
| 2024-08-22 11:05 |
Leqembi (lecanemab) godkänt i Storbritannien för behandling av tidig Alzheimers…
|
Swedish | 220.5 KB | ||
| 2024-08-22 08:34 |
Regarding rumors of an imminent approval of lecanemab in Great Britain
|
English | 175.5 KB | ||
| 2024-08-01 12:45 |
Försäljningen av Leqembi mer än dubblades – uppgick till 6,3 miljarder yen unde…
|
Swedish | 178.8 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
